Carisma Therapeutics (CARM) Stock Price

Carisma Therapeutics Price

NASDAQ·CLOSED
0.00
​
Market closed

Revenue has compounded at 27.7% per year over the past 11 years to 19.63 M USD. Carisma Therapeutics's net margin stands at -308.1%, down from -200.5% several years earlier. Carisma Therapeutics currently offers a dividend yield of about 0.18%.

Carisma Therapeutics stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Carisma Therapeutics business model & stock analysis

Carisma Therapeutics Inc., based in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing immunotherapies using macrophage and monocyte cell engineering. The company, listed on February 6, 2014, employs 17 full-time staff and is developing CT-0508, a CAR-M therapy for HER2-overexpressing solid tumors, alongside CT-0525 and other pipeline assets. Its platform aims to create transformative treatments for cancer and serious diseases through engineered myeloid cells.

Frequently asked questions about Carisma Therapeutics

6 analysts currently rate the Carisma Therapeutics stock: 0 recommend buying, 3 holding and 3 selling.

Converted at the current exchange rate, the Carisma Therapeutics share trades at 0.00 EUR (0.00 USD).

The Carisma Therapeutics share (CARM) is listed on 3 stock exchanges, including: NASDAQ (CARM), Frankfurt (W2J.F), München (W2J.MU).

The revenue cannot currently be calculated for Carisma Therapeutics.

The expected profit of Carisma Therapeutics is -22.20 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Carisma Therapeutics is currently -0.00. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Carisma Therapeutics stock.

The P/S cannot be calculated for Carisma Therapeutics currently.

The Eulerpool Quality Score for Carisma Therapeutics is 4/10.

The ISIN of Carisma Therapeutics is US14216R1014. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Carisma Therapeutics is A3DZG2. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Carisma Therapeutics is CARM. The ticker symbol is used to trade Carisma Therapeutics shares on the stock exchange.

Fair ValueTerminal
0.00 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
1.15 M USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website sesenbio.com
Currency
USD
Initial public offering
Feb 6, 2014
ISIN
US14216R1014
Cusip
14216R101
Market capitalization
8,370.00 USDMicro Cap
52-Week Range
PEG
-0.00
P/E ratio
P/Ee 2025
-0.00
P/Ee 2026
-0.00
P/Ee 2027
-0.00
P/Ee 2028
-0.00
P/Ee 2029
-0.00
P/S
P/Se
—
EV/EBIT
0.27
P/B Ratio
0.00
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
224.12 %
Last updated Nov 22, 2026, 3:50 AM

Carisma Therapeutics Peer Group

Carisma Therapeutics Ticker

FRANKFURT · W2J.FMUNICH · W2J.MUNASDAQ · CARM

Carisma Therapeutics FIGI

CARM:US · BBG001J2N453CARM:UA · BBG005SCNX58CARM:UC · BBG005SCNX67CARM:UN · BBG005SCNX85CARM:UP · BBG005SCNX94CARM:UQ · BBG005SCNXB1CARM:UB · BBG005SCNXC0CARM:UM · BBG005SCNXF7CARM:UX · BBG005SCNXG6CARM:UD · BBG005SCNXN8CARM:UF · BBG005SCNXR4CARM:VY · BBG005SCNXS3